Currently Viewing
Rare lymphoma receives a much-needed drug approval
September 28, 2009 – Elizabeth Whittington
Would winning a pink Vespa help you raise awareness for Breast Cancer Awareness Month?
September 23, 2009 – Elizabeth Whittington
Needles, giving blood and cancer flashbacks
September 22, 2009 – Kathy LaTour
Hormonal therapy for prostate cancer may cause heart problems
September 22, 2009 – Melissa Weber
What do we look for in new drugs?
September 18, 2009 – Debu Tripathy
Does cancer screening save lives?
September 17, 2009 – Melissa Weber
Weight lifting and lymphedema
September 16, 2009 – Lena Huang
Remembering Patrick Swayze
September 16, 2009 – Elizabeth Whittington
Healing through art
September 14, 2009 – Kathy LaTour

Rare lymphoma receives a much-needed drug approval

BY Elizabeth Whittington
PUBLISHED September 28, 2009
Folotyn (pralatrexate), a drug which made waves after results of a phase II trial were revealed at last year's American Society of Hematology meeting, was granted accelerated approval for peripheral T-cell lymphoma on Friday. (You can read more about the PROPEL study from CURE's 2008 ASH coverage). The approval is a first for PTCL, a rare and aggressive type of lymphoma that does not have many treatment options. The FDA based its decision on an improved overall response rate with the drug. While progression-free survival or overall survival (common endpoints in clinical trials) have not yet been demonstrated in a study, the improvement in response rate was enough for the FDA to give a green light to Folotyn because of PTCL's aggressive nature and lack of successful treatments. Additional studies of the drug will be ongoing to further assess clinical benefit. The drug's manufacturer, Allos, has established a patient assistance program to help with reimbursement issues once the drug is available, which is projected to be early October. Patients can learn more about ASAP (Allos Support for Assisting Patients) by calling 877-272-7102 or visiting
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles


Sign In

Not a member? Sign up now!

Sign Up

Are you a member? Please Log In